Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers
Abstract Zastaprazan (JP‐1366) is a novel potassium‐competitive acid blocker for the treatment of acid‐related disorders. We aimed to establish a population pharmacokinetic (PK) model of zastaprazan, thereby characterizing the PK of zastaprazan in patients with gastroesophageal reflux disease (GERD)...
Saved in:
| Main Authors: | Eunsol Yang, Inyoung Hwang, Sang Chun Ji, John Kim, SeungHwan Lee |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.13228 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis
by: Jiaqi Liu, et al.
Published: (2025-07-01) -
Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi‐physiologic population pharmacokinetic approach
by: Juyoung Khwarg, et al.
Published: (2024-12-01) -
Role of Potassium-Competitive Acid Blockers in Helicobacter pylori Eradication
by: Jong Kyu Park
Published: (2017-03-01) -
Pharmacokinetics of Pentanedioic Acid Imidazolyl Ethanamide in Healthy Volunteers
by: I. G. Gordeev, et al.
Published: (2021-05-01) -
Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers
by: Jong Kyu Park
Published: (2023-09-01)